![](https://ml.globenewswire.com/media/MmFiNmVmNGYtNGQ4NS00NjQwLWI1MmEtNjI3MDYyYzZiYTc4LTEzMDgxODA=/tiny/Aardvark-Therapeutics-Inc-.png)
Aardvark Therapeutics Announces Pricing of Initial Public Offering
SAN DIEGO, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Aardvark Therapeutics, Inc. (“Aardvark”) (Nasdaq: AARD), a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the …